CN113350566A - Preparation method of medical sponge hemostatic material - Google Patents

Preparation method of medical sponge hemostatic material Download PDF

Info

Publication number
CN113350566A
CN113350566A CN202110836513.6A CN202110836513A CN113350566A CN 113350566 A CN113350566 A CN 113350566A CN 202110836513 A CN202110836513 A CN 202110836513A CN 113350566 A CN113350566 A CN 113350566A
Authority
CN
China
Prior art keywords
parts
sodium alginate
hemostatic material
preparation
drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110836513.6A
Other languages
Chinese (zh)
Inventor
洪志达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Jinshuokang Medical Technology Co ltd
Original Assignee
Beijing Jinshuokang Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Jinshuokang Medical Technology Co ltd filed Critical Beijing Jinshuokang Medical Technology Co ltd
Priority to CN202110836513.6A priority Critical patent/CN113350566A/en
Publication of CN113350566A publication Critical patent/CN113350566A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0036—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The invention discloses a preparation method of a medical sponge hemostatic material, which comprises the following components in parts by weight: 20-30 parts of modified sodium alginate, 15-25 parts of polyvinyl alcohol, 10-16 parts of silk fibroin, 20-30 parts of hydroxypropyl starch, 8-12 parts of diacetyl tartaric acid monoglyceride and diglyceride, 6-15 parts of sorbitol and 10-14 parts of ferroferric oxide nanoparticles.

Description

Preparation method of medical sponge hemostatic material
Technical Field
The invention belongs to the technical field of medical hemostatic materials, and particularly relates to a preparation method of a medical sponge hemostatic material.
Background
The medical adhesive is a preparation, a material or a substance which can be adhered to the surface or can cause the surface to be adhered in the aspect of medical treatment, belongs to biomedical special functional adhesive, is mainly used for local adhesion and repair of organs or tissues, replaces the technical fields of traditional suturing, or combination and positioning of tissues and blood vessels for plugging and the like, and has the biomedical function besides the common adhesive bonding function and the mechanical function. Compared with the traditional methods such as suturing and nailing, the use of the medical adhesive can effectively shorten the operation time and obviously reduce the pain of patients, and is the preferred material for the current medical operation. Currently, cyanoacrylate medical adhesives have been rapidly developed and widely used clinically in recent decades. Structure CNCH of cyanoacrylate medical glue2In CCOOR, alpha-carbon atom is combined with-CN, -COOR group, so that the carbon atom at beta position generates stronger electroabsorbability, and only a very trace amount of anions (-OH, -NH) are met2) I.e., instantaneously polymerize. Because the basic substance of organism tissue is protein, and the protein is linear macro-molecule formed from amino acidThe macromolecule containing-NH at both ends2and-COOH group, the cyanoacrylate medical adhesive has the fastest polymerization speed on organism tissues and obvious performance advantage.
Sponges are a class of porous solid materials that contain a gas. In recent years, sponges have found wide application in the fields of drug release, medical dressings, cell culture, tissue engineering, and the like. Medical sponges used in biological systems are required to satisfy the following requirements for good biocompatibility, cell compatibility and histocompatibility. Biocompatibility is the first problem facing the application of biomaterials in humans and is also the key to the clinical application. The ideal hemostatic sponge has the characteristics of good porosity and hydrophilicity, higher air permeability and water absorption, moderate mechanical strength, high hemostatic efficiency, easy degradation and absorption by organisms, no toxicity, good biocompatibility and degradable absorptivity, easy tissue absorption, rich raw materials and the like. At present, the common medical sponge can not meet the requirement.
Disclosure of Invention
The invention aims to provide a preparation method of a medical sponge hemostatic material, which comprises the following components in parts by weight: 20-30 parts of modified sodium alginate, 15-25 parts of polyvinyl alcohol, 10-16 parts of silk fibroin, 20-30 parts of hydroxypropyl starch, 8-12 parts of diacetyl tartaric acid monoglyceride and diglyceride, 6-15 parts of sorbitol and 10-14 parts of ferroferric oxide nanoparticles.
Further, the preparation method of the modified sodium alginate comprises the following steps:
adding sodium alginate into a container, adding deionized water to disperse and dissolve the sodium alginate uniformly, adding 4-acetoxyl-2-azetidinone and vinyl ether, dropwise adding a hydrochloric acid solution to adjust the pH value to 6.0-6.4, stirring at the temperature of 45-50 ℃ for 1.5-3 h, cooling and drying to obtain the modified sodium alginate.
Further, the mass ratio of the sodium alginate to the deionized water is (2-3) to (5-8).
Furthermore, the mass ratio of the sodium alginate to the 4-acetoxyl-2-azetidinone to the vinyl ether is (1-1.6): (0.05-0.14): 0.12-0.24).
The preparation method comprises the following steps:
s1: adding modified sodium alginate, polyvinyl alcohol and silk fibroin into deionized water, heating to 60-65 ℃, stirring until the mixture is completely dissolved, adding hydroxypropyl starch, diacetyl tartaric acid monoglyceride and diglyceride and sorbitol into the mixture, and continuously stirring for 2-3 hours.
S2: and (4) uniformly dispersing the ferroferric oxide nano particles in the product obtained in the step S1, pouring the product into a mold, and freeze-drying to obtain the hemostatic material.
Further, the stirring speed in the step S1 is controlled to be 800-1000 rpm, and the temperature rise rate is controlled to be 1-1.5 ℃/min.
Further, the freezing speed in the step S2 is-75 to-30 ℃, the freezing drying time is 8 to 40 hours, and the vacuum degree of the freezing drying is 100 to 350 Pa.
Compared with the prior art, the invention has the following beneficial effects:
according to the invention, the volume density of the medical hemostatic sponge material is improved, so that the medical hemostatic sponge material has better formability and generates less cracks when being subjected to external force; meanwhile, the hemostatic agent has better hemostatic property and water absorption; the invention also adopts modified sodium alginate with excellent stability as a component of the medical hemostatic sponge material, and the modified sodium alginate is compounded with components with excellent hemostatic function, such as ferroferric oxide nano particles, so as to prepare the medical hemostatic sponge material with better hemostatic property, water absorption rate, and excellent mechanical property and degradation property.
Detailed Description
The following embodiments of the present invention are described in detail, and the embodiments are implemented on the premise of the technical solution of the present invention, and a detailed implementation manner and a specific operation process are given, it should be noted that, for those skilled in the art, a plurality of modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Example 1
The preparation method of the medical sponge hemostatic material comprises the following components in parts by weight: 20 parts of modified sodium alginate, 15 parts of polyvinyl alcohol, 10 parts of silk fibroin, 20 parts of hydroxypropyl starch, 8 parts of diacetyl tartaric acid monoglyceride and diglyceride, 6 parts of sorbitol and 10 parts of ferroferric oxide nanoparticles.
The preparation method of the modified sodium alginate comprises the following steps:
adding sodium alginate into a container, adding deionized water to disperse and dissolve the sodium alginate uniformly, adding 4-acetoxyl-2-azetidinone and vinyl ether, dropwise adding a hydrochloric acid solution to adjust the pH value to 6.0, stirring at the temperature of 45 ℃ for 1.5h, cooling and drying to obtain the modified sodium alginate.
Wherein the mass ratio of the sodium alginate to the deionized water is 2: 5; the mass ratio of the sodium alginate to the 4-acetoxyl-2-azetidinone to the vinyl ether is 1:0.05: 0.12.
The preparation method comprises the following steps:
s1: adding modified sodium alginate, polyvinyl alcohol and silk fibroin into deionized water, heating to 60-65 ℃, stirring until the mixture is completely dissolved, adding hydroxypropyl starch, diacetyl tartaric acid monoglyceride and diglyceride and sorbitol into the mixture, and continuously stirring for 2 hours; the stirring speed is controlled at 800rpm, and the heating rate is controlled at 1 ℃/min.
S2: uniformly dispersing ferroferric oxide nanoparticles in the product obtained in the step S1, pouring the product into a mold, and freeze-drying to obtain the hemostatic material; the freezing speed is-75 ℃, the freezing drying time is 8h, and the vacuum degree of the freezing drying is 100 Pa.
Example 2
The preparation method of the medical sponge hemostatic material comprises the following components in parts by weight: 30 parts of modified sodium alginate, 25 parts of polyvinyl alcohol, 16 parts of silk fibroin, 30 parts of hydroxypropyl starch, 12 parts of diacetyl tartaric acid monoglyceride and diglyceride, 15 parts of sorbitol and 14 parts of ferroferric oxide nanoparticles.
The preparation method of the modified sodium alginate comprises the following steps:
adding sodium alginate into a container, adding deionized water to disperse and dissolve the sodium alginate uniformly, adding 4-acetoxyl-2-azetidinone and vinyl ether, dropwise adding a hydrochloric acid solution to adjust the pH value to 6.4, stirring at the temperature of 50 ℃ for 3 hours, cooling and drying to obtain the modified sodium alginate.
The mass ratio of the sodium alginate to the deionized water is 3: 8; the mass ratio of the sodium alginate to the 4-acetoxyl-2-azetidinone to the vinyl ether is 1.6:0.14: 0.24.
The preparation method comprises the following steps:
s1: adding modified sodium alginate, polyvinyl alcohol and silk fibroin into deionized water, heating to 65 ℃, stirring until the mixture is completely dissolved, adding hydroxypropyl starch, diacetyl tartaric acid monoglyceride and sorbitol into the mixture, and continuously stirring for 3 hours; the stirring speed is controlled at 1000rpm, and the heating rate is controlled at 1.5 ℃/min.
S2: uniformly dispersing ferroferric oxide nanoparticles in the product obtained in the step S1, pouring the product into a mold, and freeze-drying to obtain the hemostatic material; the freezing speed is-30 ℃, the freezing drying time is 40h, and the vacuum degree of the freezing drying is 350 Pa.
Example 3
The preparation method of the medical sponge hemostatic material comprises the following components in parts by weight: 25 parts of modified sodium alginate, 20 parts of polyvinyl alcohol, 12 parts of silk fibroin, 24 parts of hydroxypropyl starch, 10 parts of diacetyl tartaric acid monoglyceride and diglyceride, 9 parts of sorbitol and 12 parts of ferroferric oxide nanoparticles.
The preparation method of the modified sodium alginate comprises the following steps:
adding sodium alginate into a container, adding deionized water to disperse and dissolve the sodium alginate uniformly, adding 4-acetoxyl-2-azetidinone and vinyl ether, dropwise adding a hydrochloric acid solution to adjust the pH value to 6.2, stirring at the temperature of 47 ℃ for 2 hours, cooling and drying to obtain the modified sodium alginate.
The mass ratio of the sodium alginate to the deionized water is 2.4: 6; the mass ratio of the sodium alginate to the 4-acetoxyl-2-azetidinone to the vinyl ether is 1.2:0.08: 0.18.
The preparation method comprises the following steps:
s1: adding modified sodium alginate, polyvinyl alcohol and silk fibroin into deionized water, heating to 62 ℃, stirring until the mixture is completely dissolved, adding hydroxypropyl starch, diacetyl tartaric acid monoglyceride and sorbitol into the mixture, and continuously stirring for 2.5 h; the stirring speed is controlled at 900rpm, and the heating rate is controlled at 1.2 ℃/min.
S2: uniformly dispersing ferroferric oxide nanoparticles in the product obtained in the step S1, pouring the product into a mold, and freeze-drying to obtain the hemostatic material; the freezing speed is-55 ℃, the freeze-drying time is 20h, and the vacuum degree of freeze-drying is 220 Pa.
Example 4
The preparation method of the medical sponge hemostatic material comprises the following components in parts by weight: 28 parts of modified sodium alginate, 24 parts of polyvinyl alcohol, 14 parts of silk fibroin, 28 parts of hydroxypropyl starch, 11 parts of diacetyl tartaric acid monoglyceride and diglyceride, 13 parts of sorbitol and 13 parts of ferroferric oxide nanoparticles.
The preparation method of the modified sodium alginate comprises the following steps:
adding sodium alginate into a container, adding deionized water to disperse and dissolve the sodium alginate uniformly, adding 4-acetoxyl-2-azetidinone and vinyl ether, dropwise adding a hydrochloric acid solution to adjust the pH value to 6.3, stirring at the temperature of 48 ℃ for 2.5h, cooling and drying to obtain the modified sodium alginate.
The mass ratio of the sodium alginate to the deionized water is 2.8: 7; the mass ratio of the sodium alginate to the 4-acetoxyl-2-azetidinone to the vinyl ether is 1.5:0.12: 0.21.
The preparation method comprises the following steps:
s1: adding modified sodium alginate, polyvinyl alcohol and silk fibroin into deionized water, heating to 64 ℃, stirring until the mixture is completely dissolved, adding hydroxypropyl starch, diacetyl tartaric acid monoglyceride and sorbitol into the mixture, and continuously stirring for 3 hours; the stirring speed is controlled at 950rpm, and the heating rate is controlled at 1.4 ℃/min.
S2: uniformly dispersing ferroferric oxide nanoparticles in the product obtained in the step S1, pouring the product into a mold, and freeze-drying to obtain the hemostatic material; the freezing speed is-35 ℃, the freeze-drying time is 33h, and the vacuum degree of freeze-drying is 300 Pa.
Examples of the experiments
Determination of hemostatic properties of the medical hemostatic sponge materials prepared in examples 1 to 4 in the test, unmodified starch sponge materials similar to commercially available medical hemostatic sponge materials and prepared by a self-made medical hemostatic sponge material were used as a control group to verify and evaluate hemostatic effects; establishing a rabbit ear artery wound model through animal experiments, and comparing and analyzing the hemostatic effects of different hemostatic materials; the test evaluates the hemostatic effect by comparing the hemostatic time and the amount of bleeding of different hemostatic materials, the test results are shown in table 1,
table 1. test results:
Figure BDA0003177344560000061
as can be seen from Table 1, the sponge hemostatic materials prepared in examples 1-4 of the present invention have lower bleeding amount and faster hemostatic time.

Claims (5)

1. The preparation method of the medical sponge hemostatic material is characterized in that the sponge hemostatic material comprises the following components in parts by weight: 20-30 parts of modified sodium alginate, 15-25 parts of polyvinyl alcohol, 10-16 parts of silk fibroin, 20-30 parts of hydroxypropyl starch, 8-12 parts of diacetyl tartaric acid monoglyceride and diglyceride, 6-15 parts of sorbitol and 10-14 parts of ferroferric oxide nanoparticles;
the preparation method of the modified sodium alginate comprises the following steps: adding sodium alginate into a container, adding deionized water to disperse and dissolve the sodium alginate uniformly, adding 4-acetoxyl-2-azetidinone and vinyl ether, dropwise adding a hydrochloric acid solution to adjust the pH value to 6.0-6.4, stirring at the temperature of 45-50 ℃ for 1.5-3 h, cooling and drying to obtain modified sodium alginate;
the preparation method comprises the following steps:
s1: adding modified sodium alginate, polyvinyl alcohol and silk fibroin into deionized water, heating to 60-65 ℃, stirring until the mixture is completely dissolved, adding hydroxypropyl starch, diacetyl tartaric acid monoglyceride and diglyceride and sorbitol into the mixture, and continuously stirring for 2-3 hours;
s2: and (4) uniformly dispersing the ferroferric oxide nano particles in the product obtained in the step S1, pouring the product into a mold, and freeze-drying to obtain the hemostatic material.
2. The method for preparing a medical sponge hemostatic material according to claim 1, wherein the mass ratio of sodium alginate to deionized water is (2-3) to (5-8).
3. The method for preparing a medical sponge hemostatic material according to claim 1, wherein the mass ratio of sodium alginate to 4-acetoxy-2-azetidinone is (1-1.6): (0.05-0.14).
4. The method for preparing a medical sponge hemostatic material according to claim 1, wherein the stirring speed in step S1 is controlled at 800-1000 rpm, and the temperature rise rate is controlled at 1-1.5 ℃/min.
5. The method for preparing a medical sponge hemostatic material according to claim 1, wherein the freezing speed in step S2 is-75 to-30 ℃, the freeze-drying time is 8 to 40 hours, and the vacuum degree of freeze-drying is 100 to 350 Pa.
CN202110836513.6A 2021-07-23 2021-07-23 Preparation method of medical sponge hemostatic material Pending CN113350566A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110836513.6A CN113350566A (en) 2021-07-23 2021-07-23 Preparation method of medical sponge hemostatic material

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110836513.6A CN113350566A (en) 2021-07-23 2021-07-23 Preparation method of medical sponge hemostatic material

Publications (1)

Publication Number Publication Date
CN113350566A true CN113350566A (en) 2021-09-07

Family

ID=77540236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110836513.6A Pending CN113350566A (en) 2021-07-23 2021-07-23 Preparation method of medical sponge hemostatic material

Country Status (1)

Country Link
CN (1) CN113350566A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114668883A (en) * 2022-04-21 2022-06-28 安徽大学 Preparation method of curcumin-loaded sodium alginate/polyvinyl alcohol/silk fibroin composite scaffold

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104353107A (en) * 2014-11-10 2015-02-18 苏州蔻美新材料有限公司 Medical hemostatic sponge material and preparation method thereof
CN104874013A (en) * 2015-05-22 2015-09-02 苏州市贝克生物科技有限公司 Preparation method of medical hemostatic sponge material
CN105816909A (en) * 2016-05-10 2016-08-03 北京科技大学 Method for preparing high-elasticity high-absorbency hemostatic and bacteriostatic expansive sponge
CN106279749A (en) * 2016-09-22 2017-01-04 大连工业大学 A kind of alginate and the preparation method of fibroin albumen composite sponge
CN110975000A (en) * 2019-11-25 2020-04-10 北京航空航天大学 Preparation and application of antibacterial modified exosome burn wound healing promotion biological dressing
CN113045793A (en) * 2021-04-02 2021-06-29 宁波因天之序生物科技有限公司 Medical hemostatic sponge material and preparation method thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104353107A (en) * 2014-11-10 2015-02-18 苏州蔻美新材料有限公司 Medical hemostatic sponge material and preparation method thereof
CN104874013A (en) * 2015-05-22 2015-09-02 苏州市贝克生物科技有限公司 Preparation method of medical hemostatic sponge material
CN105816909A (en) * 2016-05-10 2016-08-03 北京科技大学 Method for preparing high-elasticity high-absorbency hemostatic and bacteriostatic expansive sponge
CN106279749A (en) * 2016-09-22 2017-01-04 大连工业大学 A kind of alginate and the preparation method of fibroin albumen composite sponge
CN110975000A (en) * 2019-11-25 2020-04-10 北京航空航天大学 Preparation and application of antibacterial modified exosome burn wound healing promotion biological dressing
CN113045793A (en) * 2021-04-02 2021-06-29 宁波因天之序生物科技有限公司 Medical hemostatic sponge material and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114668883A (en) * 2022-04-21 2022-06-28 安徽大学 Preparation method of curcumin-loaded sodium alginate/polyvinyl alcohol/silk fibroin composite scaffold

Similar Documents

Publication Publication Date Title
JP4667486B2 (en) Water-soluble elastin crosslinking agent
CN111407920B (en) Biological tissue hydrogel adhesive and preparation method thereof
CN111072997B (en) High-strength self-healing hydrogel based on modified hyaluronic acid and preparation method thereof
CA2686927A1 (en) Superporous hydrogels for heavy-duty applications
CN114404649B (en) Hydrogel with pH/glucose dual-response metformin release function and preparation method and application thereof
CN111635480A (en) Anti-swelling hydrogel material and preparation method thereof
CN112920425B (en) Medical hydrogel composition, medical hydrogel and preparation method thereof
CN110522948A (en) Injection aquagel and its preparation method and application
Ye et al. In situ forming injectable γ-poly (glutamic acid)/PEG adhesive hydrogels for hemorrhage control
CN113350566A (en) Preparation method of medical sponge hemostatic material
CN104591679A (en) Modified magnesium oxychloride bone cement as well as preparation method and application thereof
Wei et al. Viscosity-controlled printing of supramolecular-polymeric hydrogels via dual-enzyme catalysis
CN103007342B (en) Biodegradable and medical tricalcium phosphate/gamma-polyglutamic acid composite and preparation method thereof
CN105920680B (en) A kind of soft tissue engineering porous support and preparation method thereof
CN106729950B (en) A kind of hemostatic material and preparation method thereof
CN115536919B (en) Modified chitosan adhesive hydrogel and preparation method and application thereof
CN108822299B (en) Hydroxylamino-terminated polyethylene glycol block polymer, preparation method thereof, hydrogel containing polyethylene glycol block polymer, preparation method and application
CN113045793A (en) Medical hemostatic sponge material and preparation method thereof
TWI287978B (en) Alginate composite fiber
CN108939132A (en) A kind of high bioactivity hyaluronic acid medical film and preparation method thereof based on the modification of low immunogenicity collagen
CN114533941B (en) Preparation method of polymer hemostatic material
CN113350565B (en) Medical adhesive material for vessel closure and preparation method thereof
CN114404650B (en) Preparation method and product of temperature-sensitive hydrogel dressing
JP3379088B2 (en) Composite for biomaterial and method for producing the same
CN114380936B (en) High-blood-absorption sodium polyacrylate resin containing polypeptide structure and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination